Drug Trial Radar · NCT04699188
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
344
Actual
Start
Feb 24, 2021
Primary completion
Jan 25, 2027
Study completion Jan 25, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a particular treatment arm, dose expansion will assess the anti-tumor activity and further assess the safety, tolerability, and PK/PD of each regimen at the maximum tolerated dose / recommended dose or lower dose.
Conditions
- KRAS G12C Mutant Solid Tumors
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Colorectal
- Cancer of Lung
- Cancer of the Lung
- Lung Cancer
- Neoplasms, Lung
- Neoplasms, Pulmonary
- Pulmonary Cancer
- Pulmonary Neoplasms
Interventions
JDQ443Drug
KRAS G12C inhibitor
TNO155Drug
SHP2 inhibitor
tislelizumabBiological
Anti PD1 antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of monotherapy or combination treatmentTime frame: 21 days
- Dose Escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: 24 months
- Dose Escalation: Frequency of dose interruptions and reductions, by treatmentTime frame: 24 months
- Dose Escalation: Dose intensity by treatmentTime frame: 24 months
- Dose Expansion: Overall response rate (ORR) per RECIST v1.1, by treatmentTime frame: 24 months
- Dose expansion: Overall intracranial response rate (OIRR) per mRANO-BMTime frame: 24 months
- Dose expansion: Incidence and severity of AEs and SAEsTime frame: 24 months
- Dose expansion: frequency of dose interruptions and reductions, by treatmentTime frame: 24 months
- Dose expansion: Dose intensity by treatmentTime frame: 24 months
- Dose expansion: ORR per RECIST 1.1 of JDQ443 single agent in patients with non-small cell lung cancer (JDQ443 dose randomization group only)Time frame: 24 months
Locations
38 sites in 16 countries. Site status is shown where the registry gives one.
Emory University School of Medicine-Winship Cancer Institute
Atlanta, Georgia
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Hillman Cancer Center
Pittsburgh, Pennsylvania
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Copenhagen, Denmark
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Villejuif, France
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Dresden, Saxony, Germany
Novartis Investigative Site
Hong Kong, Hong Kong
Novartis Investigative Site
Brescia, BS, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Novartis Investigative Site
Kashiwa, Chiba, Japan
Novartis Investigative Site
Osaka, Osaka, Japan
Novartis Investigative Site
Chuo Ku, Tokyo, Japan
Novartis Investigative Site
Koto Ku, Tokyo, Japan
Novartis Investigative Site
Amsterdam, Netherlands
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Málaga, Spain
Novartis Investigative Site
Valencia, Spain
Novartis Investigative Site
Santiago Compostela, A Coruna, Spain
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, Spain
Novartis Investigative Site
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.